Evidence map›Paper›PMID 37239960›Full record

ReviewInternational journal of molecular sciences2023

The Crucial Roles of Pitx3 in Midbrain Dopaminergic Neuron Development and Parkinson's Disease-Associated Neurodegeneration.

Xin Wang, Xi Chen, Guangdong Liu, Huaibin Cai, Weidong Le

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Xin WangInstitute of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, China.
Xi ChenInstitute of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, China.
Guangdong LiuInstitute of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, China.ORCID 0000-0002-1667-0581
Huaibin CaiTransgenic Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA.
Weidong LeInstitute of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, China.
University of Electronic Science and Technology of China · CNNational Institutes of Health · US

Funding

Molecular and Pathophysiological Study of Parkinson's DiseaseZIAAG000928 · NIA · NATIONAL INSTITUTE ON AGING · PI CAI, HUAIBIN · 2011 to 2025
$15.8M
The Function and Pathogenic Mechanisms of LRRK2/Dardarin in Parkinson's DiseaseZIAAG000944 · NIA · NATIONAL INSTITUTE ON AGING · PI CAI, HUAIBIN · 2009 to 2025
$10.2M
The Pathogenic Mechanism of ALS-related VAPB MutationZIAAG000943 · NIA · NATIONAL INSTITUTE ON AGING · PI CAI, HUAIBIN · 2009 to 2025
$6.8M
Striatal Projection Neuron Changes in Dopamine Depletion and Parkinsons DiseaseZIAAG000945 · NIA · NATIONAL INSTITUTE ON AGING · PI CAI, HUAIBIN · 2009 to 2025
$5.4M
Pathophysiological Study of Dopamine in Alzheimer's Disease and Related DemantiaZIAAG000540 · NIA · NATIONAL INSTITUTE ON AGING · PI CAI, HUAIBIN · 2020 to 2025
$2.8M
The Function and Pathogenic Mechanisms of LRRK2/Dardarin in Parkinson's DiseaseZ01AG000944 · NIA · NATIONAL INSTITUTE ON AGING · PI CAI, HUAIBIN · 2008 to 2008
$499k
Intramural NIH HHS Z01 AG000944Key Research and Development Program of Sichuan 2021YFS0382National Natural Science Foundation of China 32220103006National Natural Science Foundation of China 82271524the intramural program of National Institute on Aging, USA ZIA AG000944, AG000928
6 · The paper itself

Abstract

The degeneration of midbrain dopaminergic (mDA) neurons, particularly in the substantia nigra pars compacta (SNc), is one of the most prominent pathological hallmarks of Parkinson's disease (PD). To uncover the pathogenic mechanisms of mDA neuronal death during PD may provide therapeutic targets to prevent mDA neuronal loss and slow down the disease's progression. Paired-like homeodomain transcription factor 3 (Pitx3) is selectively expressed in the mDA neurons as early as embryonic day 11.5 and plays a critical role in mDA neuron terminal differentiation and subset specification. Moreover, Pitx3-deficient mice exhibit some canonical PD-related features, including the profound loss of SNc mDA neurons, a dramatic decrease in striatal dopamine (DA) levels, and motor abnormalities. However, the precise role of Pitx3 in progressive PD and how this gene contributes to mDA neuronal specification during early stages remains unclear. In this review, we updated the latest findings on Pitx3 by summarizing the crosstalk between Pitx3 and its associated transcription factors in mDA neuron development. We further explored the potential benefits of Pitx3 as a therapeutic target for PD in the future. To better understand the transcriptional network of Pitx3 in mDA neuron development may provide insights into Pitx3-related clinical drug-targeting research and therapeutic approaches.

Indexed as

Dopaminergic NeuronsHomeodomain ProteinsParkinson DiseaseTranscription FactorsAnimalsDopamineMesencephalonMiceDopaminehomeobox protein PITX3Homeodomain ProteinsTranscription Factorsmidbrain dopaminergic neuron developmentpaired-like homeodomain transcription factor 3 (Pitx3)Parkinson’s diseasetranscription factors

Identifiers

PMID37239960
PMCPMC10218497
OpenAlexW4376279006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.